Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Experiments were carried out in mice in which an inactivated suspension of the MEFl newborn-mouse adapted strain of Type 2 poliomyelitis virus was used as an immunizing agent. It was found that 1) the adapted strain had a far greater immunogenic potency than the standard when the animals were challenged with the homotypic strain; and 2) a significant and reproducible cross-protection was detected when the mice were challenged intraspinally with a heterotypic, Type 3 (Leon) strain.
No takes yet. Share an insight, caveat, or question.
Casals et al. (1952) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: